HALO vs. MEDP: Halozyme Therapeutics vs. Medpace Stock Comparison

Company Profile

Halozyme Therapeutics (HALO) and Medpace (MEDP) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while MEDP is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Halozyme Therapeutics (HALO) at 216.38% and Medpace (MEDP) at 117.88% turn shareholders’ equity into profit at rates above their industry benchmark ranges for ROE. That is a strong capital-efficiency signal, though leverage and the equity base still matter.

Both Halozyme Therapeutics (HALO) at 26.93% and Medpace (MEDP) at 18.24% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Halozyme Therapeutics (HALO) at 59.84% and Medpace (MEDP) at 23.12% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Halozyme Therapeutics (HALO) at 37.55% and Medpace (MEDP) at 19.97% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Halozyme Therapeutics (HALO) at -25.36% and Medpace (MEDP) at 20.98% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MEDP.

Only one side’s leverage can be read here: Medpace (MEDP) carries debt-to-equity ratio of 0.29 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Halozyme Therapeutics (HALO) nor Medpace (MEDP) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Halozyme Therapeutics (HALO) nor Medpace (MEDP) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both Halozyme Therapeutics (HALO) at 25.91 and Medpace (MEDP) at 36.26 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

On P/S ratio, both Halozyme Therapeutics (HALO) at 6.55 and Medpace (MEDP) at 6.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Medpace (MEDP) reports 31.23, ranking against industry peers normally.

Valuation Metrics